Immutep taps Charles River for IMP761 LAG-3 antibody preclinical study
Immutep Limited, an Australian biotech company specializing in LAG-3 immunotherapies for cancer and autoimmune diseases, has partnered with Charles River Laboratories to conduct a GLP toxicology study for its preclinical candidate, IMP761, targeting autoimmune diseases. Developed as a first-in-class LAG-3 agonist antibody, IMP761 aims to address the root cause of autoimmune diseases by mitigating the […]